Alvotech SANASDAQ:ALVO
- LAST PRICE13.4600
- TODAY'S CHANGE (%)-0.1400 (-1.0294%)
- Bid / Lots13.2000/ 7
- Ask / Lots15.0000/ 1
- Open / Previous Close13.5000 / 13.6000
- Day Range
- 52 Week Range
- Volume71,254
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALVO |
|---|---|---|
| 09:32 ET | 1061 | 13.5 |
| 09:36 ET | 3323 | 13.9 |
| 09:39 ET | 502 | 13.5 |
| 09:45 ET | 11672 | 13.5 |
| 09:50 ET | 5900 | 13.17 |
| 09:52 ET | 932 | 13.17 |
| 09:54 ET | 600 | 13.44 |
| 10:03 ET | 3900 | 13.19 |
| 10:06 ET | 100 | 13.19 |
| 10:08 ET | 300 | 13.0501 |
| 10:10 ET | 4800 | 13.115 |
| 10:12 ET | 2300 | 13.18 |
| 10:14 ET | 6449 | 13.2 |
| 10:15 ET | 100 | 13.21 |
| 10:24 ET | 335 | 13.3 |
| 10:53 ET | 300 | 13.215 |
| 10:55 ET | 200 | 13.22 |
| 11:02 ET | 100 | 13.305 |
| 11:40 ET | 100 | 13.305 |
| 11:42 ET | 100 | 13.23 |
| 11:44 ET | 166 | 13.305 |
| 11:45 ET | 350 | 13.3 |
| 11:49 ET | 300 | 13.3 |
| 11:54 ET | 265 | 13.4 |
| 11:56 ET | 600 | 13.31 |
| 12:02 ET | 500 | 13.36 |
| 12:05 ET | 300 | 13.49 |
| 12:07 ET | 700 | 13.49 |
| 12:12 ET | 300 | 13.49 |
| 12:18 ET | 250 | 13.5 |
| 12:21 ET | 750 | 13.34 |
| 12:23 ET | 100 | 13.42 |
| 12:30 ET | 100 | 13.42 |
| 12:32 ET | 100 | 13.46 |
| 12:34 ET | 300 | 13.35 |
| 12:36 ET | 400 | 13.35 |
| 12:41 ET | 100 | 13.42 |
| 12:45 ET | 100 | 13.42 |
| 01:03 ET | 100 | 13.48 |
| 01:44 ET | 100 | 13.46 |
| 01:53 ET | 100 | 13.48 |
| 02:00 ET | 1700 | 13.25 |
| 02:06 ET | 300 | 13.31 |
| 02:20 ET | 200 | 13.365 |
| 02:54 ET | 100 | 13.31 |
| 03:03 ET | 422 | 13.3 |
| 03:05 ET | 800 | 13.34 |
| 03:07 ET | 100 | 13.25 |
| 03:12 ET | 900 | 13.2101 |
| 03:14 ET | 200 | 13.2101 |
| 03:16 ET | 200 | 13.21 |
| 03:18 ET | 200 | 13.23 |
| 03:20 ET | 100 | 13.21 |
| 03:21 ET | 600 | 13.2 |
| 03:25 ET | 600 | 13.2 |
| 03:32 ET | 600 | 13.2001 |
| 03:36 ET | 200 | 13.22 |
| 03:38 ET | 200 | 13.24 |
| 03:39 ET | 200 | 13.25 |
| 03:41 ET | 500 | 13.24 |
| 03:45 ET | 700 | 13.21 |
| 03:48 ET | 105 | 13.2128 |
| 03:50 ET | 500 | 13.21 |
| 03:52 ET | 1033 | 13.2 |
| 03:54 ET | 1015 | 13.4886 |
| 03:59 ET | 774 | 13.46 |
Mar 17, 2023
Mar 7, 2023
Deutsche Bank Adjusts Alvotech's Price Target to $12 From $8, Maintains Hold Rating, from 10:40AM ET on Tuesday Mar 07, 2023 by MT Newswires
10:40AM ET on Tuesday Mar 07, 2023 by MT Newswires
Mar 1, 2023
BRIEF-Alvotech Reports Financial Results For Full Year 2022 And Provides Business Update, from 4:47PM ET on Wednesday Mar 01, 2023 by Thomson Reuters
4:47PM ET on Wednesday Mar 01, 2023 by Thomson ReutersAlvotech Reports Financial Results for Full Year 2022 and Provides Business Update, from 4:30PM ET on Wednesday Mar 01, 2023 by GlobeNewswire
4:30PM ET on Wednesday Mar 01, 2023 by GlobeNewswire
Feb 27, 2023
Alvotech Announces Webcast of 2022 Full Year Financial Results at 8:00 am ET on March 2, 2023, from 7:15PM ET on Monday Feb 27, 2023 by GlobeNewswire
7:15PM ET on Monday Feb 27, 2023 by GlobeNewswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Alvotech SA | 3.6B | -5.7x | --- |
Cytokinetics Inc | 3.2B | -7.8x | --- |
Cerevel Therapeutics Holdings Inc | 3.7B | -10.1x | --- |
Intellia Therapeutics Inc | 3.3B | -6.2x | --- |
CRISPR Therapeutics AG | 3.4B | -5.2x | --- |
Denali Therapeutics Inc | 3.1B | -8.8x | --- |
Company Information
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Contact Information
- Headquarters
- 9, Rue De BitbourgLUXEMBOURG, Luxembourg 1273
- Phone
- ---
- Fax
- ---
Executives
- Executive Chairman of the Board, Founder
- Robert Wessman
- Chief Executive Officer
- Mark Levick
- Deputy Chief Executive Officer
- Tanya Zharov
- Independent Deputy Chairman of the Board
- Richard Davies
- Chief Financial Officer
- Joel Morales
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.6B |
|---|---|
Revenue (TTM) | $85.0M |
Shares Outstanding | 262.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.36 |
Book Value | $-2.24 |
P/E Ratio | -5.7x |
Price/Sales (TTM) | 42.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -439.62% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
